Kisqali with hormone therapy for early-stage breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how well Kisqali (ribociclib) combined with hormone therapy works after surgery for people with early-stage HR+ HER2- breast cancer that has a high chance of coming back. It aims to gather real-world data on different treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of breast cancer called HR-positive and HER2-negative that has not spread beyond the breast or nearby lymph nodes.
- Your doctor has already decided to treat you with one of these medicines after surgery: Kisqali (ribociclib) plus an aromatase inhibitor (with or without a hormone-blocker), an aromatase inhibitor alone (with or without a hormone-blocker), or Verzenio (abemaciclib) plus endocrine therapy (with or without a hormone-blocker).
- You are 18 years or older.
- You are not taking part in any other clinical trial or another Novartis study with Kisqali.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This study observes people with early-stage hormone receptor positive, HER2-negative breast cancer who are taking ribociclib (Kisqali) with hormone therapy after surgery. It aims to see how well the treatment works and how safe it is in real life.
This trial tests whether adding the targeted therapy ribociclib (Kisqali) to radiation after surgery reduces the risk of breast cancer returning in patients with high-risk, hormone-positive breast cancer.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial studies whether adding ribociclib to standard hormone (endocrine) therapy lowers the risk of breast cancer coming back in early-stage, hormone-receptor–positive cancer. It mainly looks at safety and how well the treatment controls cancer after surgery and (sometimes) prior hormone treatment.
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.